Iovance Biotherapeutics Ownership | Who Owns Iovance Biotherapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Iovance Biotherapeutics Ownership Summary


Iovance Biotherapeutics is owned by 17.92% institutional investors, 0.33% insiders, and 81.76% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 8.70% of IOVA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.79% of its assets in Iovance Biotherapeutics shares.

IOVA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockIovance Biotherapeutics17.92%0.33%81.76%
SectorHealthcare Stocks 35.74%11.83%52.43%
IndustryBiotech Stocks 36.05%11.82%52.13%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de31.08M8.70%$109.09M
Mhr fund management28.97M8.11%$101.67M
Blackrock21.23M7.97%$170.23M
Vanguard group27.21M7.47%$74.28M
State street17.45M4.88%$61.24M
Two sigma investments, lp13.69M3.83%$48.04M
Millennium management9.41M2.63%$33.04M
Goldman sachs group8.76M2.45%$30.75M
Geode capital management8.57M2.40%$30.10M
Invenomic capital management lp8.50M2.38%$29.82M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mhr fund management28.97M7.43%$101.67M
B group1.50M3.90%$5.26M
Palo alto investors lp6.35M3.41%$22.29M
Knott david m jr1.60M3.34%$5.62M
Orion investment2.07M2.30%$7.25M
Invenomic capital management lp8.50M1.37%$29.82M
Cm management450.00K1.32%$1.58M
Rhenman & partners asset management ab2.06M0.89%$7.21M
Kennondale capital management318.19K0.81%$1.12M
Parametrica management195.88K0.78%$687.53K

Top Buyers

HolderShares% AssetsChange
Two sigma investments, lp13.69M0.04%9.29M
D. e. shaw8.02M0.02%4.19M
Vanguard group27.21M0.00%3.15M
Millennium management9.41M0.01%2.83M
Marshall wace, llp2.36M0.01%2.36M

Top Sellers

HolderShares% AssetsChange
Hood river capital management---9.22M
Long focus capital management2.10M0.19%-6.50M
Macquarie group---4.79M
Artisan partners limited partnership---4.41M
Avoro capital advisors---3.50M

New Positions

HolderShares% AssetsChangeValue
Marshall wace, llp2.36M0.01%2.36M$8.27M
Vanguard fiduciary trust2.18M0.00%2.18M$7.67M
Knott david m jr1.60M3.34%1.60M$5.62M
Voloridge investment management1.02M0.01%1.02M$3.59M
Artal group1.01M0.21%1.01M$8.11M

Sold Out

HolderChange
Global financial private client-4.00
Nbc securities-4.00
Global retirement partners-5.00
Pier 88 investment partners-10.00
Capital performance advisors llp-11.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026150-45.05%64,023,711-75.53%170.35%88-41.72%29-54.69%
Dec 31, 2025168-35.63%143,064,086-32.81%390.97%89-29.37%43-41.89%
Sep 30, 20252470.82%212,726,6064.22%631.71%118-4.07%69-1.43%
Jun 30, 2025250-18.03%220,042,797-8.11%651.20%125-19.87%74-16.85%
Mar 31, 202524-92.48%69,746,593-71.12%210.34%12-92.36%4-95.40%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv12.48M2.79%2.88K
Vanguard US Total Market Shares ETF8.71M2.66%762.45K
State Street® SPDR® S&P® Biotech ETF9.08M2.03%-89.70K
iShares Russell 2000 ETF7.91M1.77%66.65K
Hood River Small-Cap Growth Instl5.10M1.53%-
Macquarie Small Cap Core I4.08M1.22%56.67K
Invenomic Institutional5.02M1.22%9.67K
Vanguard Small Cap Index4.51M1.01%-19.32K
SPDR® S&P Biotech ETF3.56M0.98%7.96K
Delaware Small Cap Core I2.61M0.86%1.84M

Recent Insider Transactions


DateNameRoleActivityValue
Jun 05, 2025Kirby Daniel Gordon Chief Commercial OfficerBuy$55.20K
May 23, 2025Puri Raj K. Chief Regulatory OfficerBuy$9.74K
May 14, 2025Vogt Frederick G Interim CEO & General CounselBuy$42.25K
Nov 12, 2024Maynard Ryan D-Sell$503.00K
Feb 20, 2024MCPEAK MERRILL A-Buy$2.29M

Insider Transactions Trends


DateBuySell
2026 Q2--
2026 Q1--
2025 Q4--
2025 Q3--
2025 Q23-

IOVA Ownership FAQ


Who Owns Iovance Biotherapeutics?

Iovance Biotherapeutics shareholders are primarily institutional investors at 17.92%, followed by 0.33% insiders and 81.75% retail investors. The average institutional ownership in Iovance Biotherapeutics's industry, Biotech Stocks , is 36.05%, which Iovance Biotherapeutics falls below.

Who owns the most shares of Iovance Biotherapeutics?

Iovance Biotherapeutics’s largest shareholders are Blackrock funding, inc. /de (31.08M shares, 8.70%), Mhr fund management (28.97M shares, 8.11%), and Blackrock (21.23M shares, 7.97%). Together, they hold 24.78% of Iovance Biotherapeutics’s total shares outstanding.

Does Blackrock own Iovance Biotherapeutics?

Yes, BlackRock owns 7.97% of Iovance Biotherapeutics, totaling 21.23M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 170.23M$. In the last quarter, BlackRock increased its holdings by 1.3M shares, a 6.50% change.

Who is Iovance Biotherapeutics’s biggest shareholder by percentage of total assets invested?

Mhr fund management is Iovance Biotherapeutics’s biggest shareholder by percentage of total assets invested, with 7.43% of its assets in 28.97M Iovance Biotherapeutics shares, valued at 101.67M$.

Who is the top mutual fund holder of Iovance Biotherapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Iovance Biotherapeutics shares, with 2.79% of its total shares outstanding invested in 12.48M Iovance Biotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools